Candel Therapeutics, Inc. Profile Avatar - Palmy Investing

Candel Therapeutics, Inc.

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase I…

Biotechnology
US, Needham [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Candel Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of CADL's Analysis
CIK: 1841387 CUSIP: 137404109 ISIN: US1374041093 LEI: - UEI: -
Secondary Listings
CADL has no secondary listings inside our databases.